Repurposing Vinpocetine: A Potential Management Strategy for Selective Serotonin Reuptake Inhibitors (SSRI)-Induced Sexual Dysfunction
Abstract
.
1. Montejo AL, Prieto N, de Alarcón R, Casado-Espada N, de la Iglesia J, Montejo L. Management Strategies for Antidepressant-Related Sexual Dysfunction: A Clinical Approach. J Clin Med. 2019;8(10):1610.
2. Joca SRL, Sartim AG, Roncalho AL, Diniz CFA, Wegener G. Nitric oxide signalling and antidepressant action revisited. Cell Tissue Res. 2019;377(1):45–58.
3. de Aquino ACQ, Sarmento ACA, Teixeira RLA, Batista TN, de Freitas CL, Mármol JMP, et al. Pharmacological treatment of antidepressant-induced sexual dysfunction in women: A systematic review and meta-analysis of randomized clinical trials. Clinics (Sao Paulo). 2025;80:100602.
4. Dong ZC, Shi Y, Liu LJ, Feng TT, Zhou Y, Pan BW. Synthesis and pharmacological activity of vinpocetine derivatives. RSC Adv. 2024;14(12):7981–91.
5. Zhang YS, Li JD, Yan C. An update on vinpocetine: New discoveries and clinical implications. Eur J Pharmacol. 2018;819:30–4.
6. Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science. 2012;338(6103):68–72.
7. Agarwal B, Pal P, Parihar L, Singh L. Evaluation Of Protective Effect Of Vinpocetine In Reserpine-Induced Depression In Wistar Rats. Journal of Positive School Psychology. 2022;6(10).
8. Kaur S, Kumar P, Deshmukh R. Neuroprotective potential of vinpocetine in epilepsy induced co-morbid depression & cognitive dysfunction in PTZ kindled rats.
9. Uckert S, Oelke M. Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction. Br J Clin Pharmacol. 2011;72(2):197–204.
10. Petric Z, Paixão P, Filipe A, Guimarães Morais J. Clinical Pharmacology of Vinpocetine: Properties Revisited and Introduction of a Population Pharmacokinetic Model for Its Metabolite, Apovincaminic Acid (AVA). Pharmaceutics. 2023;15(10):2502.
11. Khalil NY, Bakheit AH, Alkahtani HM, Al-Muhanna T. Vinpocetine (A comprehensive profile). Profiles Drug Subst Excip Relat Methodol. 2022;47:1–54.
2. Joca SRL, Sartim AG, Roncalho AL, Diniz CFA, Wegener G. Nitric oxide signalling and antidepressant action revisited. Cell Tissue Res. 2019;377(1):45–58.
3. de Aquino ACQ, Sarmento ACA, Teixeira RLA, Batista TN, de Freitas CL, Mármol JMP, et al. Pharmacological treatment of antidepressant-induced sexual dysfunction in women: A systematic review and meta-analysis of randomized clinical trials. Clinics (Sao Paulo). 2025;80:100602.
4. Dong ZC, Shi Y, Liu LJ, Feng TT, Zhou Y, Pan BW. Synthesis and pharmacological activity of vinpocetine derivatives. RSC Adv. 2024;14(12):7981–91.
5. Zhang YS, Li JD, Yan C. An update on vinpocetine: New discoveries and clinical implications. Eur J Pharmacol. 2018;819:30–4.
6. Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science. 2012;338(6103):68–72.
7. Agarwal B, Pal P, Parihar L, Singh L. Evaluation Of Protective Effect Of Vinpocetine In Reserpine-Induced Depression In Wistar Rats. Journal of Positive School Psychology. 2022;6(10).
8. Kaur S, Kumar P, Deshmukh R. Neuroprotective potential of vinpocetine in epilepsy induced co-morbid depression & cognitive dysfunction in PTZ kindled rats.
9. Uckert S, Oelke M. Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction. Br J Clin Pharmacol. 2011;72(2):197–204.
10. Petric Z, Paixão P, Filipe A, Guimarães Morais J. Clinical Pharmacology of Vinpocetine: Properties Revisited and Introduction of a Population Pharmacokinetic Model for Its Metabolite, Apovincaminic Acid (AVA). Pharmaceutics. 2023;15(10):2502.
11. Khalil NY, Bakheit AH, Alkahtani HM, Al-Muhanna T. Vinpocetine (A comprehensive profile). Profiles Drug Subst Excip Relat Methodol. 2022;47:1–54.
| Files | ||
| Issue | Vol 21 No 2 (2026) | |
| Section | Letter to the Editor | |
| Keywords | ||
| - | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Nazari Taloki Z. Repurposing Vinpocetine: A Potential Management Strategy for Selective Serotonin Reuptake Inhibitors (SSRI)-Induced Sexual Dysfunction. Iran J Psychiatry. 2026;21(2):154-155.
